ANGIODYNAMICS INC reported third quarter of fiscal year 2026 ended February 28, 2026 results: revenue $78.4 million. Guidance raised.
“the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Net Sales $78.4 million 8.9% Med Tech Net Sales $37.3 million 19.0% Med Device Net Sales $41.1 million 1.1% • GAAP gross margin of 52.9% • GAAP loss per share of $0.19 • Adjusted loss per share of $0.07”
Earnings Releases
ANGIODYNAMICS INC reported financial results for the fiscal third quarter ended February 29, 2024.
“On April 4, 2024, AngioDynamics issued a press release announcing financial results for the fiscal third quarter ended February 29, 2024.”
Material Agreements
ANGIODYNAMICS INC entered into Settlement Agreement with Becton, Dickinson and Company, C.R. Bard, Inc. and Bard Peripheral Vascular Inc. valued at one-time lump sum payment to BD in the amount of $7 million, $3 million of which will be payable wit (effective 2024-03-31).
“On March 31, 2024, AngioDynamics and BD entered into a Settlement Agreement (the “Settlement Agreement”) to resolve the Actions.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.